CA2347734A1 - Methods and products for regulating lectin complement pathway associated complement activation - Google Patents

Methods and products for regulating lectin complement pathway associated complement activation Download PDF

Info

Publication number
CA2347734A1
CA2347734A1 CA002347734A CA2347734A CA2347734A1 CA 2347734 A1 CA2347734 A1 CA 2347734A1 CA 002347734 A CA002347734 A CA 002347734A CA 2347734 A CA2347734 A CA 2347734A CA 2347734 A1 CA2347734 A1 CA 2347734A1
Authority
CA
Canada
Prior art keywords
mbl
isolated
peptide
antibody
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002347734A
Other languages
English (en)
French (fr)
Inventor
Gregory L. Stahl
Charles D. Collard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2347734A1 publication Critical patent/CA2347734A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002347734A 1998-12-15 1999-12-15 Methods and products for regulating lectin complement pathway associated complement activation Abandoned CA2347734A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11239098P 1998-12-15 1998-12-15
US60/112,390 1998-12-15
PCT/US1999/029919 WO2000035483A1 (en) 1998-12-15 1999-12-15 Methods and products for regulating lectin complement pathway associated complement activation

Publications (1)

Publication Number Publication Date
CA2347734A1 true CA2347734A1 (en) 2000-06-22

Family

ID=22343639

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002347734A Abandoned CA2347734A1 (en) 1998-12-15 1999-12-15 Methods and products for regulating lectin complement pathway associated complement activation

Country Status (4)

Country Link
EP (1) EP1140171A4 (ja)
JP (1) JP2002532079A (ja)
CA (1) CA2347734A1 (ja)
WO (1) WO2000035483A1 (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US7273925B1 (en) 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
JP2003507338A (ja) * 1999-08-13 2003-02-25 ザ ブリグハム アンド ウイメンズ ホスピタル インコーポレイテッド レクチン補体経路（ｌｃｐ）のインヒビターおよびその使用
WO2002006460A2 (en) * 2000-07-13 2002-01-24 Jens Christian Jensenius Masp-2, a complement-fixing enzyme, and uses for it
EP1186299A1 (en) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system
EP1601377A4 (en) 2003-02-21 2009-07-15 Genentech Inc METHOD FOR THE PREVENTION AND TREATMENT OF TISSUE DAMAGE IN CONNECTION WITH ISCHEMIC REPERFUSION DAMAGE
EP2374819B1 (en) 2003-05-12 2017-03-22 Helion Biotech ApS Antibodies to MASP-2
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2007095154A2 (en) 2006-02-10 2007-08-23 The Brigham And Women's Hospital, Inc. Lectin complement pathway assays and related compositions and methods
PT3028716T (pt) 2006-10-10 2020-11-23 Regenesance B V Inibição do complemento para regeneração nervosa melhorada
ES2617920T3 (es) 2009-10-16 2017-06-20 Omeros Corporation Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2
AU2011268110B2 (en) 2010-06-19 2016-05-19 Memorial Sloan-Kettering Cancer Center Anti-GD2 antibodies
DK2694108T3 (en) 2011-04-08 2018-08-20 Univ Leicester METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
KR101641057B1 (ko) 2011-05-04 2016-07-20 오메로스 코포레이션 Masp-2 의존적 보체 활성화를 억제하는 조성물
CN105705165B (zh) 2013-03-15 2020-04-24 纪念斯隆-凯特琳癌症中心 高亲和力抗gd2抗体
CN108588033B (zh) * 2018-04-24 2021-09-24 富恩生物技术（成都）有限公司 杂交瘤细胞株、cd31单克隆抗体、制备方法及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE165980T1 (de) * 1987-08-20 1998-05-15 Childrens Medical Center Nukleinsaürefragmente, die mannose bindende fragmente vom menschlichen mannosebindenden protein kodieren
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
DE3927723A1 (de) * 1989-01-26 1990-08-02 Ulrich Prof Dr Speck N - acetylglucosamin zur buccalen anwendung
WO1991006010A1 (en) * 1989-10-11 1991-05-02 Institute Of Child Health Diagnostic procedure
AU3881493A (en) * 1992-03-19 1993-10-21 University Of British Columbia, The Method and composition for suppression of side effects of anti-inflammatory drugs
JPH06121695A (ja) * 1992-10-13 1994-05-06 Fuji Yakuhin Kogyo Kk 抗ヒトマンノース結合蛋白モノクローナル抗体およびその利用
JPH07238100A (ja) * 1994-02-25 1995-09-12 Sumitomo Electric Ind Ltd ヒトのｍａｓｐに対するモノクローナル抗体
US5998173A (en) * 1996-02-20 1999-12-07 The University Of Bristish Columbia Process for producing N-acetyl-D-glucosamine

Also Published As

Publication number Publication date
JP2002532079A (ja) 2002-10-02
EP1140171A1 (en) 2001-10-10
WO2000035483A1 (en) 2000-06-22
EP1140171A4 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
JP5745486B2 (ja) 血管新生標的免疫複合体
CA2347734A1 (en) Methods and products for regulating lectin complement pathway associated complement activation
US7273925B1 (en) Methods and products for regulating lectin complement pathway associated complement activation
US8388974B2 (en) Neovascular-targeted immunoconjugates
JP2020531048A (ja) 結合剤
AU2018241099A1 (en) Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
US20040057952A1 (en) Antibodies to non-shed Muc1 and Muc16, and uses thereof
CA2928895C (en) Antibodies against ccr9 and applications thereof
JP2002514406A (ja) 補体仲介溶解を誘発しない免疫グロブリン由来の結合分子
KR20070047246A (ko) 유로키나아제형 플라스미노겐 활성인자(ｕＰＡ)와 그의수용체(ｕＰＡＲ)의 복합체에 결합하여 하류 ｕＰＡＲ상호작용을 억제하는 리간드의 동정 및 진단 또는치료에서의 용도
EA003675B1 (ru) Белки, связывающие интерлейкин-18, их получение и применение
MX2007009222A (es) Moduladores de adam-9.
JP2005524399A (ja) Ａｌｃａｍおよびａｌｃａｍ調節因子
KR20040036684A (ko) 치료용 결합 분자
WO2003047623A1 (en) Treatment of prostate cancer by inhibitors of ncam2
EP1461001A2 (en) Cancer-associated epitope
JP2002524099A (ja) 脈管形成の調節における内皮細胞表面受容体活性の調節
US8629247B2 (en) Antibodies against prostate specific membrane antigen
JP2002518342A (ja) 抗原を変化させることにより免疫応答を産生する治療組成物
WO2013001819A1 (ja) 可溶性インテグリンα４変異体
RU2741802C2 (ru) АНТИТЕЛО К Myl9
WO2004020574A2 (en) Scfv fragment to human cathepsin l and methods of use
KR101268562B1 (ko) Ｔｌｔ-6 단백질에 대한 항체 및 그 응용
JPWO2013027658A1 (ja) 軟骨・骨破壊抑制剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead